Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter
Jul 11 • 8 tweets • 4 min read
MGCS: Monoclonal Gammopathy of clinical significance #mmsm #myeloma #MedEd #MedTwitter 🧵 #USMIRC @USMIRCNEWS
Many differential diagnosis; mostly dependent on clinical diagnosis:
- Schintzler’s Syndrome
- Scleromyxedema
- TEMPI syndrome
- Cryoglobunemia
- NXG
- Clarkson disease
1/Treatment of Myeloma:
- Transplant Eligible: (HR/SR)Dara/RVd
- Ineligible SR (DRd preferred)
Ineligible HR (VRd)
- Maintenance SR: lenalidomide
- Maintenance HR: VR (less evidence)
- 1st Relapse (HR/SR)Dara based therapy
- post triple RRMM: CAR-T then BCMA TCE then GPRC5D
#mmsm #myeloma #MedTwitter #MedEd #USMIRC @USMIRCNEWS @OncoAlert
2/Although 1q is considered as a High risk I still treat it as standard risk till I see more studies to show the impact of treatment on the outcomes!
- Regarding EMD (soft tissue) they are considered HR and treated within that group #mmsm #myeloma #MedTwitter #MedEd #USMIRC @USMIRCNEWS @OncoAlert
Jun 24, 2023 • 6 tweets • 5 min read
Hematology and Medical Oncology conference/ Kansas: Updates from ASCO 2023 #mmsm #myeloma #MedTwitter #MedEd #USMIRC Relapse myeloma still a challenge! 3 classes (IMiDs, PI and CD38 MoA) played a role to improve survival & we are looking to see BCMA Directed therapy added
BCMA CAR-T based on 2 RCT showed improved PFS compared to SOC and that is enough for me to change SOC to either Ide-Cel/Cilta-Cel #mmsm #myeloma #MedTwitter #MedEd #USMIRC